title: Role of 18F-fluorodeoxyglucose PET in the study of neuroendocrine tumors.
abstract: The most widely used PET radiopharmaceutical in daily clinical practice is (18)F-fluorodeoxyglucose (FDG). The evaluation of glycolytic metabolism by (18)F-FDG is potentially useful in identifying high-risk patients with aggressive neuroendocrine disease associated with a poor outcome. Although the use of new somatostatin analogues labeled with 68-Gallium for PET has significantly increased the sensitivity of NET imaging compared with single photon emission computed tomography and (18)F-FDG-PET, (18)F-FDG may retain an important role in managing patients with NETs owing to its high prognostic value and its higher sensitivity in delineating disease extent, especially in aggressive and high-grade tumors.
authors.affiliation: Institute of Nuclear Medicine, University College London Hospitals NHS Trust, London, UK.
authors.forename: Emmanouil
authors.initials: E
authors.lastname: Panagiotidis
authors.affiliation: Institute of Nuclear Medicine, University College London Hospitals NHS Trust, London, UK. Electronic address: jamshed.bomanji@uclh.nhs.uk.
authors.forename: Jamshed
authors.initials: J
authors.lastname: Bomanji
mesh_terms: D000310:Adrenal Gland Neoplasms / Q000000981:diagnostic imaging; D018278:Carcinoma, Neuroendocrine; D004759:Enterochromaffin Cells; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007414:Intestinal Neoplasms / Q000000981:diagnostic imaging; D018358:Neuroendocrine Tumors / Q000000981:diagnostic imaging*; D010190:Pancreatic Neoplasms / Q000000981:diagnostic imaging; D010235:Paraganglioma / Q000000981:diagnostic imaging; D010673:Pheochromocytoma / Q000000981:diagnostic imaging; D049268:Positron-Emission Tomography / Q000379:methods*; D019275:Radiopharmaceuticals; D013274:Stomach Neoplasms / Q000000981:diagnostic imaging; D013964:Thyroid Neoplasms / Q000000981:diagnostic imaging
chemical_list: D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18
keywords: (18)F-fluorodeoxyglucose (FDG); Imaging; Neuroendocrine tumors (NET); Positron emission tomography (PET); Prognosis